Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

Pathogen (Target Population)

Vaccine Envisaged

Annualized Present Value of Potential Health Benefits (IME Units)

Annualized Present Value of Expenditures on Vaccines Necessary to Achieve Potential Health Benefits ($ millions)

Rotavirue

(Infants, 0–6 months)

Attenuated high passage bovine rotavirus

521,852

853

Attenuated low passage bovine rotavirus

450,795

655

Rhesus monkey rotavirus

450,795

656

Salmonella typhi

(Children; young adults at risk; travelers from developed countries to endemic areas)

Attenuated ga1E mutant S. typhi strain TY21a

431,471

358

Aromatic amino acid dependent strains of S. typhi

194,745

152

Shigella spp.

(Infants at birth; elderly for epidemic strains)

Probably plasmid mediated outer membrane protein invasion determinant (there are a small number of promising options needing investigation to determine best approach)

222,096

92

Streptococcus A

(Children, < 3–4 years)

Synthetic M protein segment (excluding portions cross-reacting with human tissue)

180,513

554

Streptococcus pneumoniae

(Infants)

Conjugated polysaccharides, polyvalent

1,363,943

1,310

Vibrio cholera

(Children, especially < 2 years)

Genetically defined live mutant V. cholerae (A−B+ or A−B−) with respect to toxin subunit synthesis

94,986

24

Inactivated antigens

65,548

44

Yellow fever virus

(Young children)

Attenuated live virus produced in cell culture

11,127

93



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement